BPGbio and CEO Niven R. Narain, Ph.D., featured in another Drug Development & Discovery Article!
From biology-first AI to structured digital twin adoption, 4 shifts coming to biopharma R&D in 2025
From the article:
“In 2023, the composite success rate for clinical development in biopharma hit its highest level since 2018 thanks to the adoption of novel trial designs, predictive biomarkers, and digital methodologies, according to IQVIA. But waning R&D productivity is a significant industry concern. A substantial number of life science executives believe their organizations need to rethink their R&D and product-development strategies in the near future. From 2012 to 2022, inflation-adjusted R&D spending increased by 44%, from approximately $170 billion to $247 billion, according to McKinsey. The challenge is especially acute for firms that had sizable pandemic-era revenues. In September 2024, Moderna revealed plans to cut its R&D expenses by $1.1 billion, aiming to reduce annual R&D spending from $4.8 billion in 2024 to under $4 billion by 2027.
Looking ahead to 2025, two execs predict more of an evolutionary advance of digital initiatives in drug development than a revolutionary one.”
Full article: From biology-first AI to structured digital twin adoption, 4 shifts coming to biopharma R&D in 2025
About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
Media Contact:
media@bpgbio.com
